KPC presence in pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy

11Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

While reports of Klebsiella pneumoniae carbapenemase (KPC) production among Pseudomonas aeruginosa strains have emerged from a number of countries worldwide, outcome data are lacking.This is the first report evaluating how KPC production in P.aeruginosa impacts the efficacy of carbapenems by using the murine thigh infection model.Our findings suggest that the impact of KPC-2 in vivo is less pronounced than would be anticipated based on the in vitro potency.Copyright © 2013, American Society for Microbiology.All Rights Reserved.

Cite

CITATION STYLE

APA

Hagihara, M., Crandon, J. L., Urban, C. M., & Nicolaua, D. P. (2013). KPC presence in pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy. Antimicrobial Agents and Chemotherapy, 57(2), 1086–1088. https://doi.org/10.1128/AAC.01748-12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free